Can Sonic Healthcare (ASX:SHL) Restore Margins After Acquisition-Led FY26 Growth?

Aditi Sarkar

04 November 2026 11:27 PM AEDT

Can Sonic Healthcare (ASX:SHL) Restore Margins After Acquisition-Led FY26 Growth?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

FY26 Revenue increased 13% to AUD 10.87 billion, with approximately 5% organic growth.
Underlying EBITDA rose 11% to AUD 1.933 billion, but the Margin eased to 17.8%.
Operating cash flow reached AUD 1.405 billion, up 8.4%.
FY27 underlying EBITDA guidance is AUD 1.95–2.03 billion on a constant-currency basis, excluding specified IT spending.

Sonic Healthcare (ASX:SHL) operates pathology laboratories, diagnostic services and related healthcare businesses across international markets. Its FY26 performance showed higher revenue and Earnings alongside pressure on operating margins. Revenue increased 13% to AUD 10.87 billion, including approximately 5% organic growth, while underlying EBITDA rose 11% to AUD 1.933 billion. The EBITDA margin declined from 18.2% to 17.8%. Those movements matter together: revenue expanded faster than the adjusted operating earnings measure, so the Business retained a slightly smaller proportion of revenue at the EBITDA level.

Acquisitions and regional performance

Sonic Healthcare (ASX:SHL) attributed a significant share of FY26 revenue growth to acquired laboratory businesses. Its German laboratory Acquisition contributed AUD 59.1 million of profit after tax in its first full year, while Swiss laboratory operations also formed part of the expansion. Acquisition contributions and organic revenue growth are different measures: the former reflects changes in the group perimeter, while the latter helps show the performance of existing operations. Integration costs, local staffing requirements and the profitability of acquired facilities can affect how quickly additional revenue translates into group earnings.

The regional picture was uneven. UK organic revenue rose 17%, although integration delays and labour expenses remained relevant operational issues. US organic revenue was flat, and an operating review is continuing into FY27. In Switzerland, fee reductions were expected to remove approximately 3% of revenue in that market. Sonic Healthcare (ASX:SHL) therefore faces distinct operating challenges across jurisdictions rather than one uniform Demand or pricing trend.

Profitability, cash and debt

Underlying net profit after tax increased 17% to AUD 621 million in FY26, while statutory profit was AUD 608.3 million. Operating Cash Flow rose 8.4% to AUD 1.405 billion. The difference between underlying and statutory measures should be retained when comparing results because adjusted measures exclude items specified by management. The cash flow increase was slower than revenue growth, making Working Capital and capital spending relevant when assessing the conversion of accounting earnings into funds available for Debt service and investment.

Sonic Healthcare (ASX:SHL) reported gearing of 25.9%. Interest expense increased 18.6% as debt associated with acquisitions grew. The company also completed a sale and leaseback of its Brisbane hub laboratory during the year. Such transactions release capital tied up in owned property but introduce future rental commitments. The group declared a final Dividend of 63 cents per share, bringing its FY26 distribution to AUD 1.08 per share, one cent above the preceding year. Cash generation, acquisition funding and financing costs must be considered together rather than treating any single measure as decisive.

FY27 guidance and execution risks

Sonic Healthcare (ASX:SHL) guided to underlying FY27 EBITDA of AUD 1.95–2.03 billion on a constant-currency basis, excluding approximately AUD 30 million of IT transformation expenditure. The midpoint is only modestly above FY26 underlying EBITDA. Currency changes may alter reported Australian-dollar outcomes, and the excluded technology expenditure remains a cost associated with the business. The forecast does not establish that margins will recover.

Laboratory Economics depend on test volumes, labour efficiency, equipment utilisation and reimbursement arrangements. Fee changes can reduce revenue even where test volumes are stable. The continuing US review, Swiss reimbursement changes, acquisition integration and increased interest costs are therefore material considerations for the next reporting periods. Sonic Healthcare (ASX:SHL) will need to show whether operating improvements can offset these pressures.

Key Insights

FY26 delivered higher earnings and operating cash flow for Sonic Healthcare (ASX:SHL), but the EBITDA margin declined as acquisition-led growth changed the group's operating mix. FY27 guidance points to relatively limited adjusted EBITDA growth on the specified basis. Regional profitability, the US operating review, financing expenses and the cost of technology Investment remain central to the outlook.

FAQs

Q: How much of FY26 revenue growth was organic?

A: Approximately 5% organic growth was reported within total revenue growth of 13%.

Q: Why is the EBITDA margin important?

A: It declined to 17.8% from 18.2%, showing earnings grew more slowly than revenue.

Q: What is the FY27 EBITDA guidance?

A: AUD 1.95–2.03 billion, on a constant-currency basis and excluding specified IT expenditure.

Q: What was FY26 operating cash flow?

A: AUD 1.405 billion, an increase of 8.4%.

Q: Which operational issues remain relevant?

A: Acquisition integration, the US review, reimbursement changes, labour costs and interest expense.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.